U.S. Markets close in 2 hrs 37 mins

Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2019 - ResearchAndMarkets.com

The "Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Summary

According to the recently published report 'Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2019'; Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) pipeline Target constitutes close to 7 molecules.

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Lysophosphatidic acid receptor 1 is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA). Lysophosphatidic acid (LPA) receptor belongs to a group known as EDG receptors. EDG receptors mediate diverse biologic functions, including proliferation, platelet aggregation, and smooth muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis, and tumor cell invasion.

The report 'Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2019' outlays comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 5 and 1 respectively. Report covers products from therapy areas Gastrointestinal, Respiratory, Metabolic Disorders, Genito Urinary System And Sex Hormones, Male Health, Musculoskeletal Disorders, Oncology and Toxicology which include indications Non-Alcoholic Steatohepatitis (NASH), Pulmonary Fibrosis, Benign Prostatic Hyperplasia, Diabetic Nephropathy, Diabetic Neuropathy, Diarrhea, Fibrosis, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and Triple-Negative Breast Cancer (TNBC).

Scope

  • The report provides a snapshot of the global therapeutic landscape for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)
  • The report reviews Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Overview
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Companies Involved in Therapeutics Development
  • Bristol-Myers Squibb Co
  • Curadim Pharma Co Ltd
  • Novo Nordisk AS
  • Ono Pharmaceutical Co Ltd
  • RxBio Inc
  • Takeda Pharmaceutical Co Ltd
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Drug Profiles
  • BMS-002 - Drug Profile
  • CP-2090 - Drug Profile
  • EPGN-696 - Drug Profile
  • ONO-7300243 - Drug Profile
  • Rx-100 - Drug Profile
  • Small Molecule to Antagonize LPA1 for Pulmonary Fibrosis - Drug Profile
  • TAK-615 - Drug Profile
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Dormant Products
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Discontinued Products
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/w2ohog

View source version on businesswire.com: https://www.businesswire.com/news/home/20200116005424/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900